Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a BMI of greater than 28 kg/m\^2 and less than or equal to 38 kg/m\^2~* Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months~* Subject is willing to avoid major dietary changes for the duration of the study~Exclusion Criteria:~* Subject has history of diabetes (Type 1, Type 2 or steroid-induced)~* Subject has a history of hypersensitivity to pioglitazone or other thiazolidinediones~* Subject has a history of liver disease, other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis~* Subject has a history of congestive heart failure~* Subject has a active or past history of atherosclerotic heart disease, heart failure, osteoporosis, osteopenia, recurrent bone fractures, or anemia~* Subject has a history of stroke, chronic seizures, or major neurological disorder~* Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological or renal abnormalities or diseases~* Subject has a history of neoplastic disease within the past 5 years

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Pioglitazone 30 mg (Type: ACTIVE_COMPARATOR): Pioglitazone 30 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).